Evidence map›Paper›PMID 33851164›Full record

ArticlebioRxiv : the preprint server for biology2021

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2.

Fred D Mast, Peter C Fridy, Natalia E Ketaren, Junjie Wang, Erica Y Jacobs, Jean Paul Olivier, Tanmoy Sanyal, Kelly R Molloy, Fabian Schmidt, Magda Rutkowska and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Fred D Mast *Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Peter C Fridy *Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.
Natalia E Ketaren *Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.
Junjie Wang *Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York 10065, USA.
Erica Y Jacobs *Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York 10065, USA.
Jean Paul Olivier *Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Tanmoy SanyalDepartment of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, Byers Hall, 1700 4th Street, Suite 503B, University of California, San Francisco, San Francisco, CA 94158, USA.
Kelly R MolloyLaboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York 10065, USA.
Fabian SchmidtLaboratory of Retrovirology, The Rockefeller University, New York, New York 10065, USA.
Magda RutkowskaLaboratory of Retrovirology, The Rockefeller University, New York, New York 10065, USA.
Yiska WeisblumLaboratory of Retrovirology, The Rockefeller University, New York, New York 10065, USA.
Lucille M RichCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Elizabeth R VanderwallCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Nicolas DambrauskasCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Vladimir VigdorovichCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Sarah KeeganCenter for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA.
Jacob B JilerLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.
Milana E SteinLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.
Paul Dominic B OlinaresLaboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York 10065, USA.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, New York 10065, USA.
D Noah SatherCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Jason S DebleyCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
David FenyöCenter for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA.
Andrej SaliDepartment of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, Byers Hall, 1700 4th Street, Suite 503B, University of California, San Francisco, San Francisco, CA 94158, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, New York 10065, USA.
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Brian T ChaitLaboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York 10065, USA.
Michael P RoutLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.

Funding

TR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI CHAIT, BRIAN T · 2014 to 2023
$18.8M
Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3M
Regulation of the Innate Immune Response by the Epithelium in AsthmaU19AI125378 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI ZIEGLER, STEVEN F · 2016 to 2020
$9.2M
Impact of Heterogeneous Airway Epithelial ACE2 Expression and Interferon Responses on SARS-CoV2 Infectivity and ReplicationK24AI150991 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI DEBLEY, JASON S · 2020 to 2024
$1.2M
NIAID NIH HHS K24 AI150991NIAID NIH HHS R01 AI078788NIAID NIH HHS U19 AI125378NIGMS NIH HHS P41 GM109824
6 · The paper itself

Abstract

Despite the great promise of vaccines, the COVID-19 pandemic is ongoing and future serious outbreaks are highly likely, so that multi-pronged containment strategies will be required for many years. Nanobodies are the smallest naturally occurring single domain antigen binding proteins identified to date, possessing numerous properties advantageous to their production and use. We present a large repertoire of high affinity nanobodies against SARS-CoV-2 Spike protein with excellent kinetic and viral neutralization properties, which can be strongly enhanced with oligomerization. This repertoire samples the epitope landscape of the Spike ectodomain inside and outside the receptor binding domain, recognizing a multitude of distinct epitopes and revealing multiple neutralization targets of pseudoviruses and authentic SARS-CoV-2, including in primary human airway epithelial cells. Combinatorial nanobody mixtures show highly synergistic activities, and are resistant to mutational escape and emerging viral variants of concern. These nanobodies establish an exceptional resource for superior COVID-19 prophylactics and therapeutics.

Identifiers

PMID33851164
PMCPMC8043454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.